Fern Anari

Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer

Benjamin Miron, Jean Hoffman‐Censits, Fern Anari et al. · European Urology Oncology · 2020 · 76 citations · Full text

Urology, Genitourinary Cancer, Medicine +7

Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer

Arthur Winer, Pooja Ghatalia, Nicole Bubes et al. · The Oncologist · 2019 · 39 citations · Full text

Immunology, Pathology, Pharmacotherapy +16

A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN).

Daniel M. Geynisman, Philip H. Abbosh, Eric A. Ross et al. · Journal of Clinical Oncology · 2023 · 36 citations

Surgical Oncology, Cancer Management, Pathology +19

A phase II trial of risk enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN BLADDER): Interim analysis.

Daniel M. Geynisman, Philip H. Abbosh, Eric A. Ross et al. · Journal of Clinical Oncology · 2021 · 34 citations

Surgical Oncology, Cancer Management, Pathology +20

Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial

Fern Anari, John P. O’Neill, Woonyoung Choi et al. · European Urology Oncology · 2018 · 33 citations · Full text

Surgical Oncology, Urology, Genitourinary Cancer +7